Answers are grounded in this paper and cite their sources.
The FDA is requiring a boxed warning in the label of denosumab (Prolia – Amgen), a monoclonal antibody that inhibits osteoclasts, about an increased risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD; eGFR <30 mL/min/1.73 m2), particularly those on dialysis. FDA-approved indications for Prolia are listed in Table 1.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: